US EditionPublished • loading... • Updated
MeiraGTx Highlights Late-Stage Gene Therapy Pipeline at RBC Ophthalmology Conference
Summary by tickerreport.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
MeiraGTx Highlights Late-Stage Gene Therapy Pipeline at RBC Ophthalmology Conference
MeiraGTx (NASDAQ:MGTX) is advancing a portfolio of gene therapy programs across ophthalmology and other large disease areas, President and CEO Alexandria “Zandy” Forbes said during an RBC Capital Markets ophthalmology conference discussion with biotech analyst Lisa Walter. Forbes described the company as having “three late-stage programs,” including two in inherited retinal diseases (IRDs) and one […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
